Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Background Immunocompromised patients with impaired humoral immunity are at risk for
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …

Background Immunocompromised (IC) patients are at increased risk of severe and/or
prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of …

We present a retrospective study on the treatment outcomes of severely
immunocompromised patients with persistent COVID-19. The study analyzed data from 14 …

Background Monoclonal antibodies (mAbs) and antivirals have been approved for early
therapy of coronavirus disease (COVID-19), however, in the real-life setting, there are …

Here we describe the case of a 51 years old Italian woman with acute lymphoblastic
leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS …

After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls
upon immunocompromised patients who cannot mount endogenous immune response after …

Patients with hematologic malignancies can be immunocompromized because of their
disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore …

Objectives The aim of the study was to describe a cohort of B-cell-depleted
immunocompromised (IC) patients with prolonged or relapsing COVID-19 treated with …

Background The efficacy of antiviral drugs that neutralize antibody drugs and fight against
SARS-COV-2 is reported to be attenuated by genetic mutations of the virus in vitro. When B …